Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes

Wei Zhang^{1*}, Luc Girard^{1,2*}, Yu-An Zhang¹, Tomohiro Haruki¹, Mahboubeh Papari-Zareei¹, Victor Stastny¹, Hans K. Ghayee³, Karel Pacak⁴, Trudy G. Oliver⁵, John D. Minna^{1,2,6}, Adi F. Gazdar^{1,7}

¹Hamon Center for Therapeutic Oncology Research, ²Department of Pharmacology, UT Southwestern Medical Center, Dallas, TX, USA;

³University of Florida Health and Malcom Randall VA Medical Center, Gainesville, FL, USA; ⁴National Institute of Child Health and Human Development, Bethesda, MD, USA; ⁵Huntsman Cancer Institute at University of Utah, Salt Lake City, UT, USA; ⁶Department of Internal Medicine,

⁷Department of Pathology, UT Southwestern Medical Center, Dallas, TX, USA

Contributions: (I) Conception and design: All authors; (II) Administrative support: None; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: W Zhang, L Girard, YA Zhang, T Haruki; (V) Data analysis and interpretation: W Zhang, L Girard; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

*These authors contributed equally to this work.

Correspondence to: Adi F. Gazdar, Hamon Center for Therapeutic Oncology Research, University of Texas Southwestern Medical Center, Dallas, TX 75390-8593, USA. Email: adi.gazdar@utsouthwestern.edu.

Background: Small cell lung cancer (SCLC) is a deadly, high grade neuroendocrine (NE) tumor without recognized morphologic heterogeneity. However, over 30 years ago we described a SCLC subtype with “variant” morphology which did not express some NE markers and exhibited more aggressive growth.

Methods: To quantitate NE properties of SCLCs, we developed a 50-gene expression-based NE score that could be applied to human SCLC tumors and cell lines, and genetically engineered mouse (GEM) models. We identified high and low NE subtypes of SCLC in all of our sample types, and characterized their properties.

Results: We found that 16% of human SCLC tumors and 10% of SCLC cell lines were of the low NE subtype, as well as cell lines from the GEM model. High NE SCLC lines grew as non-adherent floating aggregates or spheroids while Low NE lines had morphologic features of the variant subtype and grew as loosely attached cells. While the high NE subtype expressed one of the NE lineage master transcription factors *ASCL1* or *NEUROD1*, together with *NKX2-1*, the entire range of NE markers, and lacked expression of the neuronal and NE repressor *REST*, the low NE subtype had lost expression of most NE markers, *ASCL1*, *NEUROD1* and *NKX2-1* and expressed *REST*. The low NE subtype had undergone epithelial mesenchymal transition (EMT) and had activated the Notch, Hippo and TGFβ pathways and MYC oncogene. Importantly, the high and low NE group of SCLC lines had similar gene expression profiles as their SCLC tumor counterparts.

Conclusions: SCLC tumors and cell lines can exhibit distinct inter-tumor heterogeneity with respect to expression of NE features. Loss of NE expression results in major alterations in morphology, growth characteristics, and molecular properties. These findings have major clinical implications as the two subtypes are predicted to have very different responses to targeted therapies.

Keywords: Small cell lung cancer (SCLC); neuroendocrine tumors; tumor heterogeneity; epithelial-mesenchymal transition; genetically engineered mouse model

Submitted Oct 14, 2017. Accepted for publication Feb 02, 2018.

doi: 10.21037/tlcr.2018.02.02

View this article at: <http://dx.doi.org/10.21037/tlcr.2018.02.02>

Introduction

Traditionally, lung cancers are divided into small cell lung cancer (SCLC) and the other forms of lung cancer collectively referred to as non-SCLC (NSCLC). SCLC is a highly deadly form of lung cancer with early metastatic spread and a 5-year survival of about 7% (1). There have been no major clinical advances for about three decades. For these reasons the US Congress has designated it as a “Recalcitrant Cancer” (2). SCLC is a high grade neuroendocrine (NE) tumor (3), and most tumors and cell lines express the entire program of NE cell differentiation.

The World Health Organization (WHO) Classification recognizes SCLC as a relatively homogenous tumor, with only SCLC and combined SCLC subtypes (4). In the combined form, SCLC is admixed with one of the forms of NSCLC. Thus, other than minor variations, there is only one morphological form of SCLC officially recognized. However, about 30 years ago we described a “variant” form of SCLC cell line that differed from the typical or “classic” form of SCLC in being characterized by larger cells with distinct cell borders, a moderate amount of eosinophilic cytoplasm, and a single nucleus with a prominent central nucleolus and paranucleolar chromatin clearing (5,6). Classic lines often grew as non-

adherent cell aggregates or as true spheroids. By contrast, variant cell lines had different growth characteristics, often growing as loosely aggregated or single cells, with varying degrees of substrate adherence, sometimes growing in single cell linear aggregates or “Indian file” pattern. Many variant lines were from post therapy tumors that had recurred, and *Myc* family amplification was more frequent than in the classic lines. The variant lines were more radioresistant than the classic lines with a prominent “shoulder” in the radioresponse curve, indicating the ability to repair and recover from lower radiation doses (7). Other investigators found similar features in SCLC cell lines that they had established (8,9). The Seneca Valley virus shows selective tropism for the variant subtype (10). In addition to tumors and cell lines, the variant subtype or its equivalent has been described in GEM models of SCLC (11,12). A summary of the published reports of the variant form and its properties are summarized in *Table 1*.

While the variant subtype represents a major morphological variation of SCLC, often with increased growth and cloning abilities, it is also associated with decreased or absent expression of NE cell features. Loss or decreased expression of NE features has also been described in tumors (17) and cell lines without any mention of altered morphological features. Loss of NE properties may be

Table 1 Properties of variant cell lines. Most of the information is from the references cited, although some data are presented in this report. In some reports the variant term is used, while in others it is inferred from the description of the SCLC cells

More frequent in tumors recurring after initial response to therapy (5,6)
More frequent expression of <i>MYC</i> family gene expression (5,6) and promoted by <i>MYC</i> expression <i>in vivo</i> (11)
Altered cellular morphology (5,6)
Altered cell line growth characteristics (5,6)
Rapid growth and increased cloning efficiencies (5,6,11)
Increased resistance to radiation exposure (7)
Increased sensitivity to Seneca Valley virus (10)
Frequent partial or complete loss of NE cell properties (5,6)
<i>HRAS</i> transfection selectively induces altered (variant) morphology in SCLC cell line (13)
Classic and variant cell lines vary in expression of extracellular matrix proteins (14)
Classic and variant cell lines differ in their responses to retinoic acid (15)
Expression of <i>REST</i> gene, an inhibitor of neural and NE properties (this report and 48) in cells that have lost NE properties
Often associated with loss of <i>ASCL1</i> master transcription factor and expression of <i>NEUROD1</i> master transcription factor or loss of both transcription factors (11,16)
Variant morphology identified in original human tumor tissues (8) and in genetically engineered mouse models (GEMMs) (10-12)

associated with alterations in the expression of the master transcription regulator *ASCL1*, a member of the basic helix-loop-helix (BHLH) family of transcription factors. The major purpose of this manuscript is to document the heterogeneity of SCLC, with respect to morphology, growth characteristics, other biological properties and the complex relationship of NE differentiation with respect to *ASCL1*, the Notch pathway and other inhibitors and promoters of NE differentiation. In order to do this quantitatively, we developed a scoring system for NE differentiation, which is outlined in this manuscript. We also document heterogeneity in expression of certain oncogenes associated with SCLC (Myc gene family, *NFIB*, *MYB*). We compare these features in tumors and cell lines and GEM models, as the latter are one of the major forms of in vitro models available for the study of a cancer such as SCLC when human tumor materials for study are scant (18).

Methods

Establishment of a NE score for lung cancers

Additional details about our methodology can be found elsewhere, where we used a similar approach to develop a gene expression identifier for the classification of NSCLC tumors (19). Multiple steps were performed to generate a NE score. First, expression array data (Affymetrix HuGene 1.0 ST) were compared between 8 matched normal adrenal medulla (NE) samples and 8 normal adrenal cortex (non-NE) samples. From a volcano plot, we identified 50 genes differentially expressed between the two groups (25 NE and 25 non-NE genes). We next applied this adrenal-based signature to a large panel of SCLC and NSCLC lines (profiled on Illumina WG6-V3) and identified 41 NE cell lines (31 SCLCs and 10 NE-NSCLCs) and 87 non-NE cell lines (NSCLCs only). These two groups of cell lines were then used to generate a different 50-gene lung cancer-specific NE signature from the most highly differentially expressed genes (25 genes overexpressed in the NE cell lines, 25 genes overexpressed in the non-NE cell lines). A quantitative NE score was generated from this signature using the formula: NE score = (correl NE – correl non-NE)/2 where correl NE (or non-NE) is the Pearson correlation between expression of the 50 genes in the test sample and expression of these genes in the NE (or non-NE) cell line group. This score has a range of -1 to +1 where a positive score predicts for NE while a negative score predicts for non-NE cell types. The higher the score

in absolute value, the better the prediction.

Identification of SCLC cell lines

Many of the cell lines were initiated at the National Cancer Institute several years ago and the original pathology materials were not available for review. Our criteria for calling cell lines as SCLC were as follows: (I) pathological diagnosis of SCLC of the original diagnostic material; (II) cell culture with the growth properties characteristic of SCLC; (III) morphological features of classic or variant SCLC by examination of formalin fixed, paraffin embedded agarose cell blocks (20) or cell line derived xenografts (CCXs); and (IV) loss of Rb protein expression by Western blotting (21), or inactivating mutations of the *RB1* gene by sequencing. As rare SCLC tumors lack inactivation of *RB1* (17), in one case we identified a cell line with intact Rb protein expression as SCLC. The basis for SCLC designation in this case depended on the presence of other SCLC cell characteristics not discussed herein.

SCLC tumors and cell lines

RNASeq data were available for 81 resected SCLC tumors (17) and for 70 SCLC cell lines that we established and characterized in our laboratory (22,23). With the exception of one cell line, *RB1* gene was inactivated in all cases as determined by whole exome sequencing for inactivating mutations or by Western blot for protein expression. Mutations of the *TP53* gene were present in all cases. The provenance of all cell lines was confirmed by use of the GenePrint 10 kit for short tandem repeats (Promega), and confirmed free of mycoplasma contamination by the e-Myco plus kit (Boca Scientific).

Cell lines were examined in the living state by inverted microscopy to determine growth patterns. For determination of cytological morphology, cell lines were pelleted, fixed in formalin, paraffin embedded, sectioned and stained with hematoxylin and eosin. For some cases, histological slides of the original tumors from which cell lines were derived or CCXs were available for review.

We calculated the Pearson correlation coefficient between the NE score and genes or pathways known or suspected to be involved in the pathogenesis of SCLC. For SCLC tumors, the expression of highest expressed isoform was chosen and all the expression values were converted as log2 levels. $P < 0.05$ is considered statistically significant.

Figure 1 Generation of a 50-gene NE signature. Left panel: the top 25 genes overexpressed in NE cell lines and the top 25 genes overexpressed in non-NE cell lines were selected from a volcano plot (the colors of the dots are shown on a gradient scale from blue to red in proportion to the distance between each point and the origin (0, 0). Red dots, highly significant). Right panel: the heat map shows that these 50 genes separate lung NE from non-NE lines. NE, neuroendocrine.

GEM model

Mouse primary lung tumors from *Rb1^{fl/fl}Trp53^{fl/fl}MycT58A^{LSL/LSL}* mice (RPM, Jackson Laboratory stock No. 029971) (11) were micro-dissected under sterile conditions. Individual tumors were processed to single cell suspension by mechanical and chemical separation with incubation in 0.25% Trypsin-EDTA (1X) Solution (Gibco, Waltham, MA, USA) for 20 min. Cell suspensions were filtered through a 100 μ m cell strainer and re-suspended in RPMI media with 10% FBS, 1% Penicillin/Streptomycin and L-glutamine and grown in uncoated tissue culture flasks or coated 100 mm plates.

RNA isolation and RNA-Seq was performed as previously described (11) for primary mouse RPM tumors and cell lines. Mouse lung tumor RNA-Seq data are available at NCBI GEO: GSE89660. Eleven RPM tumors (histology of the tumors not available for review) and eight double negative cell lines were scored for NE and the Pearson correlation coefficient between the NE score and genes was calculated.

Results

Development and validation of a NE score for lung cancers

As described in Methodology, we developed a numeric

score for evaluating the degree of NE differentiation in lung tumors and cell lines. The top 25 genes most strongly associated with NE differentiation and the top 25 genes not associated with NE differentiation were selected for inclusion into the NE signature score (Figure 1, Tables S1,S2). The score ranges from -1.0 to 1.0, with NE differentiation values ranging from 0 to 1.0, and non-NE scores (i.e., indicating absence of NE differentiation) ranging from 0 to -1.0. These genes clearly differentiated lung NE from non-NE cell lines (Figure 1).

The top 25 genes for NE differentiation include a range of known and previously unknown NE and neural genes: neural (n=11), NE (n=2), both neural and NE (n=6), and other (n=6) (Table S3). Some of them, *ASCL1*, chromogranin A (*CHGA*) (24) and *INSM1* (25) are in use as immunostains for the pathological diagnosis of SCLC and other NE tumors.

The top 25 genes negatively associated with NE differentiation (Table S4) had a wide range of functions including substrate attachment, cell migration, invasion and metastasis, calcium signaling, inflammation and immunity, fibrinolysis and blood clotting, HIPPO signaling, caveolae, G protein signaling, epithelial cell differentiation, CNS development, and the cell cycle. Note that, many of these genes have multiple functions.

We evaluated the sensitivity and specificity of the score in

Figure 2 Evaluation of the NE gene signature in various public and private datasets of NE and other lung tumors. The score ranges from -1.0 to 1.0. Positive score predicts for NE while negative score predicts for non-NE. Multiple platforms (RNAseq, Affymetrix, Illumina and custom gene expression microarray) were used. GEO accession numbers are shown when available (17,19,26,27). NE, neuroendocrine.

public and private datasets of available NE and other lung tumors (Figure 2). Of the adenocarcinomas and squamous cell carcinomas in the well documented TCGA database, only 1% expressed positive NE scores. Of carcinoid tumors, 92% had high NE scores, while 8% had lower positive scores and only one had a negative score. The NSCLC cell lines demonstrated considerable heterogeneity. A subgroup of NSCLC lines, previously known to express NE features, including *ASCL1* expression, had relatively high NE scores. We had referred to these lines as NSCLC-neuroendocrine or NSCLC-NE cell lines (28). On review of the original histology slides, CCXs and/or agar plugs, most, if not all, could be reclassified as lung NE tumors (other than SCLC), including atypical carcinoids and large cell NE carcinomas (data not shown). These cell lines will be described in detail elsewhere, and will not be discussed further in this report. Non-malignant tissues and immortalized respiratory epithelial cells (29) had negative scores. The signature is cross platform, with a very high concordance (98%) between RNASeq and microarray expression data and can also be applied to murine *in vitro* systems (GEM models and cell lines).

NE scores of SCLC tumors and cell lines

We applied the NE score to SCLC tumors and cell lines (Figure 3). We considered samples with values lower than 1 standard deviation (SD) as having low/negative values and the others as having high NE scores. By this criterion, 13/81 (16%) of tumors and 7/70 (10%) of cell lines had low NE scores.

Heterogeneity of SCLC

As images of tumors were not available, morphology and growth characteristics were limited to cell lines (Figure 4). Cell culture growth characteristics and pathological examination of cell line pellets or CCXs were performed on about 50 of the cell lines. Almost all cell lines in the high NE score group had *in vitro* growth characteristics of spheroids or irregular floating clusters, although some also had an adherent subpopulation. By contrast, all cell lines in the low NE score group grew *in vitro* as loosely attached cells or as mixtures of attached and loosely aggregated or single floating cells. Examination of FFPE cell line pellets indicated

Figure 3 Heterogeneity of NE scores in SCLC tumors and cell lines. The distribution of NE scores in SCLC tumors and cell lines is displayed. Samples whose values were below that of 1 standard deviation (1 SD) were regarded as having low or negative scores, with the remainder having high NE scores. NE, neuroendocrine; SCLC, small cell lung cancer.

that the high NE cell lines had classic SCLC morphology with occasional giant cells, although a few had prominent nucleoli without perinucleolar chromatin clearing. The low NE score SCLC cell lines examined consisted of cells with variant features or mixtures of classic and variant cells.

The Myc driven GEM model we studied could also be divided into NE high (most tumor specimens) and low phenotypes (all cell lines after 14 or more days in culture). The cell lines were dual negative for *Ascl1* and *Neurod1*, and grew as large, loosely aggregated or partially attached cells. When inoculated subcutaneously into mice, the tumors showed a minor classic morphology subtype, while most of the cells were larger and more closely resembled human large cell carcinomas rather than the variant form of SCLC (Figure 5).

Pathway deregulation in NE high and low subgroups

We performed Pearson correlations between the NE scores and the expression of genes/pathways related to NE differentiation and SCLC pathogenesis. Very similar or identical findings were present in human SCLC and GEM model tumors and cell lines (Table 2).

NE marker expression

The NE signature is composed of the top genes

overexpressed in a group of NE cell lines, so it is not surprising that the NE score has a strong positive correlation with several known NE genes, including *ASCL1*, *NEUROD1*, *CHGA*, *INSM1*, *SYP* and *BEX1*, as well as the related gene *NKX2-1*. Conversely the NE score was negatively correlated with *REST* and *ASCL2* (Table 2).

Relationship between expression of *ASCL1*, *NEUROD1*, *ASCL2* and the NE score

The basic loop-helix-loop transcription factors *ASCL1* and *NEUROD1*, both of which play important roles in regulating expression of NE properties (16). We therefore correlated the expression of *ASCL1* and *NEUROD1* in tumors and cell lines (Figure 6, upper panel). The data suggested that the tumors and cell lines fell into four groups: (I) *ASCL1* high; (II) *NEUROD1* high; (III) dual high; or (IV) dual low. The largest group was the *ASCL1* high group, although dual low groups were present in both tumors (14.8%) and cell lines (10%). Comparison with the NE scores (Figure 6, lower panel) indicated that there was a strong association between the low NE group and the dual low samples. As shown in Figure 7, the expression of *ASCL2* was negatively correlated with *ASCL1*, and expressed in some of the NE low human SCLC tumors. However, *ASCL2* was not expressed in the dual negative cell lines derived from the GEM model (data not shown).

Notch pathway

As seen in Table 2 and Figure 8, several Notch genes as well as *HES1* were negatively correlated with the NE score, while others (*DLL3*, *DLK1*, *HES6*) were positively correlated.

Epithelial mesenchymal transition (EMT)

Expression of EMT associated genes *VIM*, *SNAI2* and *CD44* were negatively correlated with the NE score, while *CDH1* showed no correlation.

Myc family

Of the three Myc family members, only *MYC* was negatively correlated with the NE score.

Hippo pathway

Expression of several members of the Hippo pathway were negatively correlated with the NE score, including *AJUBA*, *YAP1*, *WWTR1*, *TEAD2*, and *TEAD3*.

TGFβ pathway

Expression of the TGF beta pathway genes *TGFB1*,

Figure 4 Cell culture and cell line xenograft appearances of classic (NCI-H128) and variant (NCI-H82) forms of SCLC. (A) Classic cell line NCI-H128 has a high NE score, grows as floating spheroids (illustrated) or clusters of non-adherent cells. (B) Variant cell line NCI-H82, having MYC gene amplification and over expression, grows as loosely attached cells, either singly or in small aggregates, sometimes in single cell rows ("Indian file" pattern). (C) Xenograft formed after subcutaneous inoculation of NCI-H128 in an immunosuppressed mouse shows relatively small cells with indistinct cell borders, and nuclei having a "salt and pepper" distribution of chromatin and relatively small nucleoli. These appearances are typical for those of SCLC (classic morphology). (D) NCI-H82 cell line xenograft shows somewhat larger loosely aggregated cells with distinct cell borders, larger nuclei with single prominent nucleoli and peri-nucleolar chromatin clearing (variant morphology). (A,B) Phase contrast appearance of living cultures photographed by inverted microscope; (C,D) tissue section of xenograft tumor, formalin fixed, paraffin embedded, stained with hematoxylin and eosin.

Figure 5 Appearances of dual negative cell lines and resultant cell line derived tumors from the Myc driven GEM model (11) (also see text). (A) Phase contrast image of cell line derived from culture of an original tumor after an *in vitro* culture period greater than 14 days. The cells grow as relatively large, loosely attached floating cells or as cells partially attached to the substrate. There is a tendency to grow in single cell rows ("Indian file" pattern). (B) Histological appearances of a subcutaneous tumor after inoculation of the cultured tumor cells. While some cells resemble the classic form of SCLC (arrow), most of the cells are larger than those of classic SCLC, and have one or more prominent nucleoli with paranucleolar chromatin clearing. While the appearances have some resemblance to the human variant form of SCLC, the greater intercellular heterogeneity more closely resembles the appearances of the large cell (undifferentiated) form of human NSCLC. Formalin fixed, paraffin embedded section, stained with hematoxylin and eosin. SCLC, small cell lung cancer; NSCLC, non-small cell lung cancer.

Table 2 Pathways and genes positively or negatively correlated with the NE score (with few exceptions, data from tumors, cell lines and GEM models were concordant)

Regulators/pathways	Gene name	SCLC tumors (n=81)		SCLC cell lines (n=70)		Myc-driven GEMM	
		Pearson r	P value	Pearson r	P value	Pearson r	P value
NE markers and regulators	<i>ASCL1</i>	0.68	2E-12	0.49	2E-05	0.97	3E-11
	<i>NEUROD1</i>	0.31	0.004	0.18	0.14	0.88	7E-07
	<i>SYP</i>	0.84	6E-23	0.9	1E-25	N/A	N/A
	<i>INSM1</i>	0.81	2E-20	0.86	3E-21	0.93	6E-09
	<i>BEX1</i>	0.78	9E-18	0.8	9E-17	N/A	N/A
	<i>CHGA</i>	0.77	3E-17	0.79	9E-16	0.98	1E-12
	<i>NKX2-1</i>	0.6	8E-08	0.48	3E-05	0.9	1E-07
	<i>RCOR2</i>	0.33	0.003	0.33	0.005	0.82	2E-05
	<i>ASCL2</i>	-0.42	1E-04	-0.28	0.02	N/A	N/A
Notch pathway	<i>REST</i>	-0.85	1E-23	-0.92	3E-29	-0.95	3E-10
	<i>NOTCH1</i>	-0.46	1E-05	-0.37	0.001	-0.74	3E-04
	<i>NOTCH2</i>	-0.6	4E-09	-0.71	4E-12	-0.93	7E-09
	<i>NOTCH3</i>	-0.42	9E-05	-0.63	6E-09	0.77	1E-04
	<i>HES1</i>	-0.39	3E-04	-0.25	0.04	-0.81	3E-05
	<i>DLL3</i>	0.64	1E-10	0.65	9E-10	0.97	9E-12
	<i>DLK1</i>	0.44	4E-05	0.29	0.01	0.44	0.06
	<i>HES6</i>	0.42	7E-05	0.45	1E-04	0.85	4E-06
	<i>HEY1</i>	0.24	0.03	0.28	0.02	0.51	0.03
EMT	<i>VIM</i>	-0.62	5E-10	-0.48	2E-05	-0.98	7E-14
	<i>SNAI2</i>	-0.4	2E-04	-0.09	0.44	-0.95	6E-10
	<i>CD44</i>	-0.52	6E-07	-0.63	5E-09	-0.96	7E-11
	<i>CDH1</i>	0.02	0.83	-0.19	0.12	0.56	0.01
Myc family	<i>MYC</i>	-0.66	3E-11	-0.4	6E-04	N/R	N/R
	<i>MYCL</i>	0.12	0.27	0.24	0.05	N/R	N/R
	<i>MYCN</i>	-0.02	0.86	0.05	0.66	N/R	N/R
Hippo pathway	<i>AJUBA</i>	-0.81	4E-20	-0.63	5E-09	-0.97	2E-12
	<i>YAP1</i>	-0.56	5E-08	-0.69	4E-11	-0.96	2E-10
	<i>WWTR1</i>	-0.6	2E-09	-0.7	2E-11	-0.94	4E-09
	<i>TEAD2</i>	-0.55	1E-07	-0.51	7E-06	-0.87	1E-06
	<i>TEAD3</i>	-0.5	2E-06	-0.55	9E-07	-0.91	8E-08
	<i>TEAD1</i>	0.46	2E-05	0.36	0.002	-0.62	0.005
	<i>TGFB1</i>	-0.47	9E-06	-0.32	0.007	-0.68	0.001
TGFβ pathway	<i>TGFB2</i>	-0.63	2E-10	-0.35	0.003	-0.84	5E-06
	<i>SMAD3</i>	-0.5	2E-06	-0.66	5E-10	-0.87	2E-06
	<i>SMAD4</i>	0.46	2E-05	0.29	0.01	-0.65	0.003
	<i>MYB</i>	-0.4	2E-04	-0.4	5E-04	0.8	4E-05
Other oncogenes	<i>SOX2</i>	0.31	0.004	0.14	0.25	0.66	0.002
	<i>EZH2</i>	0.3	0.007	0.1	0.39	0.42	0.07
	<i>NFIB</i>	0.24	0.03	0.07	0.55	0.94	4E-09
	<i>SLFN11</i>	-0.17	0.13	-0.1	0.43	N/A	N/A
	<i>BCL2</i>	-0.21	0.06	-0.17	0.16	-0.46	0.05

N/A, not available; N/R, not relevant (Myc-driven model); NE, neuroendocrine; SCLC, small cell lung cancer.

Figure 6 Expression of NE transcription factors *ASCL1* and *NEUROD1* in SCLC tumors and cell lines. In both tumors and cell lines, four RNA expression subtypes can be identified (upper panel): (I) *ASCL1* high, (II) *NEUROD1* high, (III) dual high and (IV) dual low. The expression values of *ASCL1* and *NEUROD1* (FPKM) were log2 transformed. The dual low subtype was associated with a low NE score (lower panel). ***, $P<0.001$ (t -test). NE, neuroendocrine; SCLC, small cell lung cancer.

Figure 7 Expression of NE transcription factor *ASCL2* in SCLC tumors. Left panel, the correlation between *ASCL2* expression and *ASCL1* expression in SCLC tumors. Right panel, *ASCL2* expression in NE high and NE low SCLC tumors. The expression values of *ASCL1* and *ASCL2* (FPKM) were log2 transformed. NE, neuroendocrine; SCLC, small cell lung cancer.

TGFBR2 and *SMAD3* were negatively correlated with the NE score, while *SMAD4* was positively correlated.

Other genes of interest

Other genes whose expressions were positively correlated with the NE score were *SOX2*, *EZH2* and *NFIB* (borderline significance in tumors) while *MYB* was negatively correlated. Expression of *BCL2* and *SLFN11* were not correlated.

Discussion

According to the WHO classification, there is a single morphological form of SCLC, although it may be combined with NSCLC elements (4). Since the discovery by Bensch and coworkers that SCLC tumors (and bronchial carcinoids and pulmonary NE cells) had dense core granules (30), the ultrastructural hallmark of NE cells, SCLC has been regarded as a NE tumor. More than 30 years ago we

Figure 8 Examples of positive and negative correlations between the NE scores and expression of indicated genes. Pearson correlation coefficient was calculated in 81 SCLC tumors. The expression values of the genes (FPKM) were log2 transformed. NE, neuroendocrine; SCLC, small cell lung cancer.

described the variant form of SCLC cell lines, which had altered morphology and growth characteristics, and loss of some NE cell features (5,31). Since that time, the variant form has been described in human tumors and xenografts, and more recently in GEM models. A number of observers have described a modest number of changes associated with the variant subtype (*Table 1*).

While most SCLC tumors and cell lines morphologically resemble the WHO description of SCLC and express the entire spectrum of NE cell markers, our data indicate that an important subset have low or absent NE differentiation and may have altered (variant) morphology and altered growth characteristics. Other published works have noted heterogeneity in SCLC tumors and in vitro models, as summarized in *Table 3*, although a variety of terminologies have been applied to the identified or implied NE high and low phenotypes. In order to accurately correlate the effects of loss of NE features with expression of other genes and pathways, a quantitative measurement of NE cell properties was essential.

We have developed and validated a robust scoring system for NE differentiation in lung cancer tumors and cell lines. The 50 gene-based scoring system uses 25 genes whose expression was most highly correlated with NE differentiation, and 25 genes whose expression was most highly negatively correlated with NE differentiation. This system can also be applied to patient-derived xenografts (PDXs)(data not shown) and to GEM models (*Table 2*). In addition, the scoring system can cross platforms as it is applicable to various microarray and RNASeq derived data. The system has the advantage of including a positive score (0 to +1), indicating NE differentiation, and a negative score (0 to -1) indicating the degree of “non-NE” differentiation. The lower the negative score, the more confidence that NE differentiation is lacking. It should be noted that a negative score does not rule out the possibility that some NE markers are expressed. For instance, *ASCL1*, the reputed master regulator of NE differentiation, may be expressed in NE stem cells without expression of the NE cell program (36). As the scoring system was tailored for lung cancers, its

Table 3 Nomenclature and terminology for NE expression heterogeneity in SCLC tumors, cell lines and GEM models

Authors	Specimen types	NE high subtype	NE low subtype	Drug sensitivity
Zhang <i>et al.</i> (this article)	Tumors (N=81), cell lines (N=70), GEM model	High NE	Low NE	N/A
George <i>et al.</i> (17)	Tumors (N=81), GEM model	Group 2 (high NE)	Group 1 (low NE)	N/A
Cardnell <i>et al.</i> (32)	Tumors (N=26), cell lines (N=63)	High TTF1/low cMYC	High cMYC/low TTF1	TTF1 high cells are sensitive to Rova-T antibody-drug conjugate, and myc high cells are sensitive to aurora kinase A inhibitors
Udyavar <i>et al.</i> (33)	Tumors (N=28), cell lines (N=53)	NE/epithelial (NE)	Non-NE/mesenchymal (ML)	NE/ML hybrid type is drug resistant
Ito <i>et al.</i> (34)	Tumors (N=41), cell lines (N=14)	YAP1 negative/NE marker positive	YAP1 positive/NE marker negative	YAP1 positive cases are more chemo-resistant
Mollaoglu <i>et al.</i> (11)	GEM model Tumors (N=81), cell lines (N=34)	NE, ASCL1 positive MYC-low, AS-CL1-high (group A)	MYC-driven, NEUROD1 positive or NE low MYC-high; NEUROD1-high (group C) or NE low (group B)	Myc-driven SCLCs are chemo-sensitive, vulnerable to Aurora kinase inhibitors
Lim <i>et al.</i> (35)	GEM model	NE	Notch active non-NE	Notch active cells are relatively chemo-resistant
Calbo <i>et al.</i> (12)	GEM model	Neuroendocrine marker profile	Mesenchymal marker profile	N/A

Heterogeneity of NE expression in SCLC has been described in the literature, but multiple terminologies have been utilized for the NE low subtype. N/A, not available or relevant; NE; neuroendocrine; SCLC, small cell lung cancer; GEM, genetically engineered mouse.

375 application to other NE tumor and cell types remains to be
376 determined.
377 The scoring system confirmed that almost all (99%)
378 NSCLC tumors lack NE differentiation. While most SCLC
379 tumors and cell lines morphologically resemble the WHO
380 description of SCLC and express the entire spectrum of
381 NE cell markers, our data indicate that an important subset
382 of SCLC have low or absent NE differentiation and may
383 have altered (variant) morphology and altered growth
384 characteristics. We chose to call tumors and cell lines that
385 had NE scores below 1 SD as samples with low scores,
386 although some may be truly negative. For SCLC tumors,
387 the images were not available for us to correlate NE
388 differentiation (or its lack) with morphology. However, for
389 cell lines, most of those with low scores had some or all the
390 features of variant cells. We used the NE score to determine
391 the relationship, positive or negative, between NE
392 differentiation and several genes and pathways important
393 in the pathogenesis of SCLC. Our studies confirmed some
394 previously identified associations with NE differentiation
395 or other pathways. It also identified several previously

unknown gene associations. Of interest, in several pathways, 396
individual genes were either positively or negatively 397
correlated with NE differentiation, indicating complicated 398
sets of checks and balances within specific pathways. It is 399
important to point out that in this report we utilized gene 400
expression data for our analyses, and that RNA and protein 401
expression are not always concordant. 402
While our original observations indicated that variant cell 403
lines often were derived from tumors recurring after initial 404
response to therapy and that myc family overexpression was 405
frequent, our current study indicates the relatively frequent 406
presence of low or absent NE differentiation in (mostly) 407
untreated series of resected SCLC tumors. Unfortunately, 408
we did not have access to the morphology of these tumors, 409
and were unable to assess the relationship of this subset 410
with the variant morphology. As mentioned in *Table 3*, other 411
citations have also noted an association between the low 412
NE phenotype and responses to chemotherapy and targeted 413
therapies. 414
Our current knowledge of what genes contribute to NE 415
cell differentiation is currently limited to a modest number 416

(perhaps 10–12). Our studies indicate that the actual gene number is far greater and includes many neural genes not previously regarded as having a NE cell association. A small number (6 of 25) of the top genes lack a previously known neural or NE association. The 25 genes most negatively associated with NE cell differentiation encompassed a wide range of functions/pathways.

ASCL1 is expressed in most SCLC tumors and cell lines and its expression is tightly linked to NE differentiation. Some tumors with equivocal or negative scores expressed *ASCL1*, suggesting the possibility that they represent NE or neural stem cells. *NEUROD1*, which has been suggested as an alternative regulator of NE differentiation in a subset of SCLC (10,16), was expressed in a large subset of tumors and cell lines, almost all of them with positive NE scores. However, SCLC cells expressing *NEUROD1* usually also expressed *ASCL1*, making it difficult to assess the relationship of *NEUROD1* with NE differentiation. Currently, it is not known whether “dual positive” SCLC cells express both transcription factors and whether they have heterogeneous expression of one or the other. Most tumors and all but one cell line lacking NE differentiation had low or absent expression of these transcription factors (“dual negative SCLC”), suggesting another alternative master regulator. We have identified expression of *ASCL2* in some of the “dual negative” tumors and cell lines, with weak or modest expression in a minority of NE positive samples. *ASCL2* is closely related to *ASCL1*, and belongs in the BHLH family of transcription factors, and is involved in the determination of the neuronal precursors in the peripheral nervous system and the central nervous system. It is also expressed in certain gastro-intestinal cells and tumors (37,38), and its expression is a prognostic factor in lung squamous cell and breast cancers (39,40), and is associated with metastases in osteosarcomas (41).

The Myc-driven GEM model we studied rapidly develops tumors that are initially *Ascl1* associated, but soon undergo a change to a *Neurod1* expressing low NE phenotype. Cell lines derived from microdissected tumors were initially non-adherent spheroids (similar to most human SCLC cell lines), but within 14 days became loosely aggregated and partially adherent like the human variant form. These cell lines were dual negative for expression of the master transcription factors *Ascl1*, *Neurod1*, and *Ascl2*. We studied the cell lines at this later, more advanced phenotype and found their properties to closely resemble the low NE phenotype in human tumors and cell lines. However, the low NE cell lines from the GEM model

lacked expression of *Ascl2*, and the morphology of their xenografts more closely resembled that of human large cell carcinoma rather than the variant subtype. We presume such a progression may have occurred *in vivo* if the mice had survived for longer periods of time. In the original description of the model (11) the *Neurod1* expression was associated with the low NE phenotype. In retrospect, including the data presented herein, we can postulate that *Neurod1* expression (at least in this model) accounts for a third phenotype intermediate in expression of its NE properties between the high and low phenotypes.

Expressions of several other well-established NE cell markers were highly positively correlated with the NE scores. Chromogranin A (*CHGA*) is a member of the chromogranin/secretogranin family of NE secretory proteins and is located in secretory vesicles of neurons and endocrine cells. This gene product is a precursor to three biologically active peptides, vasostatin, pancreastatin, and parastatin, which are negative modulators of the NE system. It is one of the better known NE cell products, and is often used for the identification of NE cells by immunostain.

The zinc finger transcription factor insulin associated 1 (*INSM1*), along with *NEUROD1* and *FOXA2*, maintain the mature gene expression program in beta-cells (42). It is also essential for the neuronal phenotype in some brain cells (43,44). *INSM1* is a transcriptional repressor, blocking expression of the Notch signaling *HES1* and *REST* (see below) by binding to its corepressors *RCOR1* and *RCOR2*, thus maintaining *ASCL1* expression (45,46). *INSM1* binds to the *HES1* promoter and represses *HES1*, which is a key negative regulator of NE differentiation. *INSM1* is increasingly being used as an immunostaining marker for NE cells and tumors (25) and its expression is very tightly correlated with the NE score. The establishment of the NE scoring system identified *BEX1* as the top NE associated gene. *BEX1* (brain expressed X-linked 1) plays a role in neuronal and myoblast development and has been reported to be a marker for NE cells (47,48). However, it may play a wider role and be involved in cell cycle control and act as a tumor suppressor gene in some situations (49).

NKX2-1 (also known as *TTF1*) is a transcription factor with limited tissue expression (brain, thyroid and the lung). Its expression in the lung is mainly in club cells and alveolar type II cells where it is crucial for the development of the peripheral lung, as well as in bronchial NE cells (50). It is expressed in most adenocarcinomas of the lung, where it functions as a lineage specific oncogene but can also act as a tumor suppressor (51,52). High expression of *NKX2-1* is

characteristic of lung (and thyroid) NE cells and tumors (53), although its function in lung NE cells is not understood. Its expression in SCLC is tightly correlated with expression of *ASCL1* and NE properties, and, thus, it may play a role in NE differentiation in the lung. *NKX2-1* has also been tightly correlated with *DLL3* expression (see below) in SCLC and this correlation was validated at the protein level further supporting our findings (32).

RE1 silencing transcription factor (*REST*) encodes a transcriptional repressor that represses neuronal and NE genes in non-neuronal and non-NE tissues and thus serves as a master negative regulator of neurogenesis (54,55), including SCLC cells (35). It is expressed in almost all non-neuronal and non-NE tissues, including NSCLC. Thus, as expected, it is strongly negatively correlated with the NE score.

Notch signaling is a key negative regulator of NE differentiation in SCLC (17,56), and may function as a tumor suppressor. Mutations in the Notch pathway genes are frequent in SCLC (17). Several Notch receptors are negatively correlated with the NE score, as is *HES1*, a negative regulator of NE differentiation. By contrast, *HES6*, an inhibitor of Notch signaling, is positively correlated. Non-NE Notch-active small-cell lung cancer cells are slow growing, consistent with a tumor-suppressive role for Notch, but these cells are also relatively chemoresistant and provide trophic support to NE tumor cells, consistent with a pro-tumorigenic role (35). The *DLL3* gene codes for a Notch ligand and is a transcriptional target of *ASCL1* (57). Unlike the other Notch ligands, it does not stimulate Notch signaling, but functions as an inhibitor. *DLL3* expression is tightly linked to expression of *ASCL1* and NE differentiation. Rovalpituzumab tesirine (ROVA-T) is a *DLL3*-targeted antibody-drug conjugate, which has shown encouraging single agent anti-tumor activity in *DLL3* expressing lung NE carcinomas (58). Our results would suggest that SCLC tumors that have lost NE (and *DLL3*) expression would be resistant to ROVA-T therapy. In addition to *DLL3*, expression of *DLK1*, another inhibitor of Notch signaling, was also associated with the high NE phenotype (17).

Epithelial to mesenchymal transition (EMT) is a fundamental developmental process that is reactivated in wound healing and in a variety of diseases including cancer where it promotes migration/invasion and metastasis, lack of cell to cell adhesion, resistance to treatment, immune evasion and generation and maintenance of cancer stem cells (59,60). Many of these properties are present in the

low NE subtype. Reprogramming of the epigenome is associated with induction of EMT. Loss of the epithelial cell marker E-cadherin (*CDH1*) and gain of the intermediate filament vimentin (*VIM*) are among the hallmarks of EMT. Clonal cells having variant like morphology and with loss of NE features were isolated from cultures of the prototype GEM Model for SCLC (12). These clones showed EMT with expression of *VIM*. The NE score was strongly negatively associated with *VIM*, suggesting that the variant subtype undergoes EMT. In addition, *SNAI2*, commonly known as SLUG, a zinc finger transcriptional repressor, which downregulates expression of *CDH1* in premigratory neural crest cells and has anti-apoptotic properties (60), was negatively correlated with NE differentiation, although the findings were only significant in SCLC tumors. These findings are consistent with earlier observations that variant SCLC cells have increased growth rates, decreased cell-to-cell adhesion and cloning efficiencies (see Table 1). EMT can be induced in different ways, most notably by a group of transcriptional repressor proteins including *SNAIL* and *SNAI2* which recognize specific DNA-binding sites within E-boxes, regulatory regions of their target genes. E-boxes are also bound by many BHLH developmental regulators leading to competition among these factors and EMT-inducing repressors. *SNAIL* and *SNAI2* compete with the stem cell factor *ASCL2* for binding to an E-box, suggesting a possible link between *SNAI2*, *ASCL2* and EMT in “dual negative” cells.

All three members of the myc family (*MYC*, *MYCL* and *MYCN*) are frequently amplified or over-expressed in SCLC tumors and cell lines (61–63). Over expression of family members is mutually exclusive. *MYC* expression (but not of the other family members) was strongly negatively correlated with the NE score, consistent with previous studies (11,32). *MYC* amplification in SCLC tumors is associated with shortened survival (64). Of major potential therapeutic importance, inhibition of *AURKA* and *AURKB* selectively inhibit growth of myc family over-expressing SCLC cell lines and causes polyploidy (11,65).

The Hippo signaling pathway is highly conserved and is a central regulator of organ size (66,67). Genetic perturbation of this pathway in mouse models results in massively enlarged organs accompanied by tumor formation. The pathway consists of a core kinase cassette consisting of a pair of serine/threonine kinases (*MST1* and *MST2*) and related genes. The pathway limits tissue growth by phosphorylating the homologous oncogenes *YAP1* and *TAZ* (also known as *WWTR1*) which results in their ubiquitin mediated

Figure 9 Summary of the main differences between NE high and low subtypes of SCLC. The NE high subtype usually has classic SCLC morphology, a high NE cell score with high expression of *ASCL1* and most or all NE markers, expression of *NKX2-1*, the Notch inhibitors *DLL3* and *DLK1*, and an epithelial phenotype. *NEUROD1* expression is more variable. By contrast, the low NE phenotype has low or absent expression of *ASCL1* and *NEUROD1* (“dual low”), low or absent expression of NE cell markers, activation of Notch, HIPPO and TGF β pathway genes and profound epithelial to mesenchymal (EMT) transition resulting in a mesenchymal phenotype. *REST*, an inhibitor of NE differentiation, is expressed while *MYC* is often over-expressed. Some but not all dual negative cases express *ASCL2*, possibly acting as an alternative driver transcription factor. Many dual negative tumor cells exhibit the variant form of SCLC. NE, neuroendocrine; SCLC, small cell lung cancer.

609 proteolysis. *YAP1* plays a critical role in the self-renewal of
 610 airway stem cells. Germline mutations of *YAP1* predisposes
 611 for lung adenocarcinoma with high familial penetrance (68).
 612 *YAP1* promotes tissue growth by regulating transcription
 613 factors including the TEADs and SMADs, and may be
 614 accompanied by chemoresistance (34). The main Hippo
 615 pathway effectors, *YAP1* and *TAZ* are overexpressed in
 616 variant cell lines with loss of NE properties, accompanied by
 617 relatively high expression of two of the three TEAD genes
 618 (*TEAD2* and *TEAD3*). In addition, *AJUBA*, an important
 619 negative regulator of HIPPO signaling, is negatively
 620 associated with NE properties, and may contribute to the
 621 high levels of *YAP1* and *TAZ* in non-NE SCLC cell lines, as
 622 has been reported previously (69). Inhibition of *YAP1* offers
 623 a potential therapeutic approach for SCLC cells that lack
 624 NE properties (66).

625 TGF β is a cytokine that exerts multiple biological
 626 functions, and which has a bi-directional role in different
 627 cancers, serving either as an oncogene or a tumor
 628 suppressor gene. In SCLC it has been reported to function
 629 as a tumor suppressor and to suppress *ASCL1*, and the
 630 pathway is repressed by *EZH2* (70). We found a negative

correlation between the NE score and the TGF β pathway,
 in particular with the genes *TGFBR2* and *SMAD3*. These
 findings are consistent with *ASCL1* (and the NE pathway)
 being down regulated in the low NE tumor group.

Other oncogenes also appeared to play important roles
 indistinguishing the high and low NE subgroups. The
 transcription factor *MYB* plays a key role as a regulator of stem
 cells in some tissues. It is over-expressed in several tumors,
 where it may act as an oncogene (71). *MYB* and *NFIB* fusion
 products are present in most adenoid cystic carcinomas (72).
MYB over-expression was described in a small series of SCLC
 cell lines (73). Our findings confirm that over-expression
 of *MYB* occurs in a relatively high percentage of SCLC
 tumors and cell lines. *MYB* was negatively correlated with
 NE expression in tumors and cell lines, but had a positive
 correlation in the *MYC* driven GEM model.

Of interest, expression of some genes, important in the
 pathogenesis of SCLC, was not significantly correlated to
 NE differentiation. These included *NFIB* (74), *SLFN11*
 (75,76), *BCL2* (28), *SOX2* and *EZH2* (70,77).

Figure 9 is a summary of the main differences between
 the NE high and low subtypes. As shown in a GEM

model (11) or in a SCLC cell lines (33), this process is a dynamic one, with transition from NE high to NE low phenotype or toward a hybrid state. Whether changes in the opposite direction (NE low to NE high) can occur is currently unknown. The NE high subtype is associated with classic morphology, expression of the NE program of markers, epithelial cell phenotype, expression of *NKX2-1* and the Notch pathway inhibitors *DLL3* and *DLK1*. The NE low phenotype is associated with variant morphology, low or absent expression of the NE markers, activation of *MYC*, *REST*, Notch, Hippo and TGF β pathways and profound EMT. In most cases, high NE expression is associated with expression of the master transcription factor *ASCL1*. In some cases, however, as exemplified by a GEM model and in human tumors and cell lines (11,16,17), the alternative neural transcription factor *NEUROD1* is activated, either with or without expression of *ASCL1*. *NEUROD1* expression is associated with varying levels of NE expression, but the low NE subtype usually has loss of both of these master transcription factors. In the low NE phenotype, in some cases, especially in human SCLC tumors, and some cell lines, the alternative master transcription factor *ASCL2* is expressed.

Our findings indicate that the NE score can be utilized to separate NE high and low subsets of SCLC tumors and cell lines. Of interest, approximately similar frequencies of low NE samples were noted in resected tumors (16%, almost all from untreated patients) and from cell lines (10%, mostly derived from recurring tumors from previously treated patients). There was more than 90% concordance between the NE score and gene and pathway associations, indicating the high relevance of cell lines, most of which retained the typical appearances and high NE scores decades after their establishment.

Our findings are of high potential clinical importance. As we enter the era of targeted therapies, many of which are likely to target NE or related genes, understanding the heterogeneity of SCLC will be crucial for the identification of NE high and low subsets more likely to respond to specific therapies. Clearly, “tumor heterogeneity is a sort of written history of a particular cancer from which we can learn”, and “which could lead to more effective cancer therapies and prevention methods” (78).

Acknowledgements

Funding: This work was supported by grants from the National Cancer Institute, Bethesda, MD, USA:

“Specialized Program in Research Excellence in Lung Cancer”, P50 CA70907 and the “Small Cell Lung Cancer Consortium Coordinating Center” U24CA213274, and 1R21CA216504-01A1 (TG Oliver).

Footnote

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

- Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. *Nat Rev Cancer* 2017;17:765.
- H.R. 733 — 112th Congress: Recalcitrant Cancer Research Act of 2012. www.GovTrack.us. 2011. February 2, 2018. Available online: <https://www.govtrack.us/congress/bills/112/hr733>
- Swarts DR, Ramaekers FC, Speel EJ. Molecular and cellular biology of neuroendocrine lung tumors: evidence for separate biological entities. *Biochim Biophys Acta* 2012;1826:255-71.
- Travis WD, Brambilla E. World Health Organization Classification of Lung and Pleural Tumors. 3rd ed. Berlin: Springer-Verlag, 2015.
- Gazdar AF, Carney DN, Nau MM, et al. Characterization of variant subclasses of cell lines derived from small cell lung cancer having distinctive biochemical, morphological, and growth properties. *Cancer Res* 1985;45:2924-30.
- Carney DN, Gazdar AF, Bepler G, et al. Establishment and identification of small cell lung cancer cell lines having classic and variant features. *Cancer Res* 1985;45:2913-23.
- Carney DN, Mitchell JB, Kinsella TJ. In vitro radiation and chemotherapy sensitivity of established cell lines of human small cell lung cancer and its large cell morphological variants. *Cancer Res* 1983;43:2806-11.
- de Leij L, Postmus PE, Buys CH, et al. Characterization of three new variant type cell lines derived from small cell carcinoma of the lung. *Cancer Res* 1985;45:6024-33.
- Berendsen HH, de Leij L, de Vries EG, et al. Characterization of three small cell lung cancer cell lines established from one patient during longitudinal follow-up. *Cancer Res* 1988;48:6891-9.
- Poirier JT, Dobromilskaya I, Moriarty WF, et al. Selective tropism of Seneca Valley virus for variant subtype small cell lung cancer. *J Natl Cancer Inst* 2013;105:1059-65.
- Mollaoglu G, Guthrie MR, Bohm S, et al. MYC Drives

- 749 Progression of Small Cell Lung Cancer to a Variant
750 Neuroendocrine Subtype with Vulnerability to Aurora
751 Kinase Inhibition. *Cancer Cell* 2017;31:270-85.
- 752 12. Calbo J, van Montfort E, Proost N, et al. A functional role
753 for tumor cell heterogeneity in a mouse model of small cell
754 lung cancer. *Cancer Cell* 2011;19:244-56.
- 755 13. Mabry M, Nakagawa T, Nelkin BD, et al. v-Ha-ras
756 oncogene insertion: a model for tumor progression of
757 human small cell lung cancer. *Proc Natl Acad Sci U S A*
758 1988;85:6523-7.
- 759 14. Scarpa S, Morstyn G, Carney DN, et al. Small cell
760 lung cancer cell lines: pure and variant types can be
761 distinguished by their extracellular matrix synthesis. *Eur*
762 *Respir J* 1988;1:639-44.
- 763 15. Doyle LA, Giangiulo D, Hussain A, et al. Differentiation
764 of human variant small cell lung cancer cell lines to
765 a classic morphology by retinoic acid. *Cancer Res*
766 1989;49:6745-51.
- 767 16. Borromeo MD, Savage TK, Kollipara RK, et al. ASCL1
768 and NEUROD1 Reveal Heterogeneity in Pulmonary
769 Neuroendocrine Tumors and Regulate Distinct Genetic
770 Programs. *Cell Rep* 2016;16:1259-72.
- 771 17. George J, Lim JS, Jang SJ, et al. Comprehensive genomic
772 profiles of small cell lung cancer. *Nature* 2015;524:47-53.
- 773 18. Gazdar AF, Hirsch FR, Minna JD. From Mice to Men and
774 Back: An Assessment of Preclinical Model Systems for the
775 Study of Lung Cancers. *J Thorac Oncol* 2016;11:287-99.
- 776 19. Girard L, Rodriguez-Canales J, Behrens C, et al.
777 An Expression Signature as an Aid to the Histologic
778 Classification of Non-Small Cell Lung Cancer. *Clin*
779 *Cancer Res* 2016;22:4880-9.
- 780 20. Mansy SS, Abbas MA, Yehia HA, et al. Value of the
781 innovated technique agarose cell block in improving the
782 sensitivity of urine cytology in cases of bladder carcinoma.
783 *Ultrastruct Pathol* 2006;30:379-85.
- 784 21. Shimizu E, Coxon A, Otterson GA, et al. RB protein status
785 and clinical correlation from 171 cell lines representing
786 lung cancer, extrapulmonary small cell carcinoma, and
787 mesothelioma. *Oncogene* 1994;9:2441-8.
- 788 22. Phelps RM, Johnson BE, Ihde DC, et al. NCI-Navy
789 Medical Oncology Branch cell line data base. *J Cell*
790 *Biochem Suppl* 1996;24:32-91.
- 791 23. Gazdar AF, Minna JD. NCI series of cell lines: An
792 historical perspective. *J Cell Biochem Suppl* 1996;24:1-11.
- 793 24. Travis WD. Pathology and diagnosis of neuroendocrine
794 tumors: lung neuroendocrine. *Thorac Surg Clin*
795 2014;24:257-66.
- 796 25. Rosenbaum JN, Guo Z, Baus RM, et al. INSM1: A
Novel Immunohistochemical and Molecular Marker for
Neuroendocrine and Neuroepithelial Neoplasms. *Am J*
Clin Pathol 2015;144:579-91.
26. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive
genomic analysis identifies SOX2 as a frequently amplified
gene in small-cell lung cancer. *Nat Genet* 2012;44:1111-6.
27. Fernandez-Cuesta L, Peifer M, Lu X, et al. Frequent
mutations in chromatin-remodelling genes in pulmonary
carcinoids. *Nat Commun* 2014;5:3518.
28. Augustyn A, Borromeo M, Wang T, et al. ASCL1 is a
lineage oncogene providing therapeutic targets for high-
grade neuroendocrine lung cancers. *Proc Natl Acad Sci U*
S A 2014;111:14788-93.
29. Sato M, Larsen JE, Lee W, et al. Human Lung
Epithelial Cells Progressed to Malignancy through
Specific Oncogenic Manipulations. *Mol Cancer Res*
2013;11:638-50.
30. Bensch KG, Corrin B, Pariente R, et al. Oat-cell
carcinoma of the lung. Its origin and relationship to
bronchial carcinoid. *Cancer* 1968;22:1163-72.
31. Carney DN, Gazdar AF, Nau M, et al. Biological
heterogeneity of small cell lung cancer. *Semin Oncol*
1985;12:289-303.
32. Cardnell RJ, Li L, Sen T, et al. Protein expression of
TTF1 and cMYC define distinct molecular subgroups of
small cell lung cancer with unique vulnerabilities to aurora
kinase inhibition, DLL3 targeting, and other targeted
therapies. *Oncotarget* 2017;8:73419-32.
33. Udyavar AR, Wooten DJ, Hoeksema M, et al. Novel
Hybrid Phenotype Revealed in Small Cell Lung Cancer by
a Transcription Factor Network Model That Can Explain
Tumor Heterogeneity. *Cancer Res* 2017;77:1063-74.
34. Ito T, Matsubara D, Tanaka I, et al. Loss of YAP1 defines
neuroendocrine differentiation of lung tumors. *Cancer Sci*
2016;107:1527-38.
35. Lim JS, Ibaseta A, Fischer MM, et al. Intratumoural
heterogeneity generated by Notch signalling promotes
small-cell lung cancer. *Nature* 2017;545:360-4.
36. Vasconcelos FF, Castro DS. Transcriptional control of
vertebrate neurogenesis by the proneural factor Ascl1.
Front Cell Neurosci 2014;8:412.
37. Jubb AM, Hoefflich KP, Haverly PM, et al. Ascl2
and 11p15.5 amplification in colorectal cancer. *Gut*
2011;60:1606-7; author reply 7.
38. Yan KS, Kuo CJ. Ascl2 reinforces intestinal stem cell
identity. *Cell Stem Cell* 2015;16:105-6.
39. Xu H, Zhao XL, Liu X, et al. Elevated ASCL2 expression
in breast cancer is associated with the poor prognosis of

- patients. *Am J Cancer Res* 2017;7:955-61.
40. Hu XG, Chen L, Wang QL, et al. Elevated expression of ASCL2 is an independent prognostic indicator in lung squamous cell carcinoma. *J Clin Pathol* 2016;69:313-8.
 41. Liu MH, Cui YH, Guo QN, et al. Elevated ASCL2 expression is associated with metastasis of osteosarcoma and predicts poor prognosis of the patients. *Am J Cancer Res* 2016;6:1431-40.
 42. Jia S, Ivanov A, Blasevic D, et al. *Insm1* cooperates with *Neurod1* and *Foxa2* to maintain mature pancreatic beta-cell function. *EMBO J* 2015;34:1417-33.
 43. Jacob J, Storm R, Castro DS, et al. *Insm1* (IA-1) is an essential component of the regulatory network that specifies monoaminergic neuronal phenotypes in the vertebrate hindbrain. *Development* 2009;136:2477-85.
 44. Rosenbaum JN, Duggan A, Garcia-Anoveros J. *Insm1* promotes the transition of olfactory progenitors from apical and proliferative to basal, terminally dividing and neuronogenic. *Neural Dev* 2011;6:6.
 45. Jia S, Wildner H, Birchmeier C. *Insm1* controls the differentiation of pulmonary neuroendocrine cells by repressing *Hes1*. *Dev Biol* 2015;408:90-8.
 46. Monaghan CE, Nechiporuk T, Jeng S, et al. REST corepressors RCOR1 and RCOR2 and the repressor INSM1 regulate the proliferation-differentiation balance in the developing brain. *Proc Natl Acad Sci U S A* 2017;114:E406-15.
 47. Khazaei MR, Halfter H, Karimzadeh F, et al. *Bex1* is involved in the regeneration of axons after injury. *J Neurochem* 2010;115:910-20.
 48. Hofsl E, Wheeler TE, Langaas M, et al. Identification of novel neuroendocrine-specific tumour genes. *Br J Cancer* 2008;99:1330-9.
 49. Fernandez EM, Diaz-Ceso MD, Vilar M. Brain expressed and X-linked (*Bex*) proteins are intrinsically disordered proteins (IDPs) and form new signaling hubs. *PLoS One* 2015;10:e0117206.
 50. La Rosa S, Marando A, Gatti G, et al. *Achaete-scute homolog 1* as a marker of poorly differentiated neuroendocrine carcinomas of different sites: a validation study using immunohistochemistry and quantitative real-time polymerase chain reaction on 335 cases. *Hum Pathol* 2013;44:1391-9.
 51. Snyder EL, Watanabe H, Magendantz M, et al. *Nkx2-1* represses a latent gastric differentiation program in lung adenocarcinoma. *Mol Cell* 2013;50:185-99.
 52. Yamaguchi T, Hosono Y, Yanagisawa K, et al. *NKX2-1/TTF-1*: an enigmatic oncogene that functions as a double-edged sword for cancer cell survival and progression. *Cancer Cell* 2013;23:718-23.
 53. La Rosa S, Chiaravalli AM, Placidi C, et al. *TTF1* expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. *Virchows Arch* 2010;457:497-507.
 54. Thiel G, Ekici M, Rossler OG. *RE-1* silencing transcription factor (*REST*): a regulator of neuronal development and neuronal/endocrine function. *Cell Tissue Res* 2015;359:99-109.
 55. Gao Z, Ure K, Ding P, et al. The master negative regulator *REST/NRSF* controls adult neurogenesis by restraining the neurogenic program in quiescent stem cells. *J Neurosci* 2011;31:9772-86.
 56. Sriuranpong V, Borges MW, Ravi RK, et al. Notch signaling induces cell cycle arrest in small cell lung cancer cells. *Cancer Res* 2001;61:3200-5.
 57. Saunders LR, Bankovich AJ, Anderson WC, et al. A *DLL3*-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. *Sci Transl Med* 2015;7:302ra136.
 58. Rudin CM, Pietanza MC, Bauer TM, et al. *Rovalpituzumab tesirine*, a *DLL3*-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. *Lancet Oncol* 2017;18:42-51.
 59. Roche J, Gemmill RM, Drabkin HA. Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. *Cancers (Basel)* 2017;9:72.
 60. Lamouille S, Xu J, Derynck R. Molecular mechanisms of epithelial-mesenchymal transition. *Nat Rev Mol Cell Biol* 2014;15:178-96.
 61. Little CD, Nau MM, Carney DN, et al. Amplification and expression of the *c-myc* oncogene in human lung cancer cell lines. *Nature* 1983;306:194-6.
 62. Nau MM, Brooks BJ, Battey J, et al. *L-myc*, a new *myc*-related gene amplified and expressed in human small cell lung cancer. *Nature* 1985;318:69-73.
 63. Johnson BE, Brennan JF, Ihde DC, et al. *myc* family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer. *J Natl Cancer Inst Monogr* 1992;(13):39-43.
 64. Alves RC, Meurer RT, Roehle AV. *MYC* amplification is associated with poor survival in small cell lung cancer: a chromogenic in situ hybridization study. *J Cancer Res Clin Oncol* 2014;140:2021-5.
 65. Helfrich BA, Kim J, Gao D, et al. *Barasertib* (AZD1152), a

- Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo. *Mol Cancer Ther* 2016;15:2314-22.
66. Pan D. YAPing Hippo Forecasts a New Target for Lung Cancer Prevention and Treatment. *J Clin Oncol* 2015;33:2311-3.
67. Harvey KF, Zhang X, Thomas DM. The Hippo pathway and human cancer. *Nat Rev Cancer* 2013;13:246-57.
68. Chen HY, Yu SL, Ho BC, et al. R331W Missense Mutation of Oncogene YAP1 Is a Germline Risk Allele for Lung Adenocarcinoma With Medical Actionability. *J Clin Oncol* 2015;33:2303-10.
69. Horie M, Saito A, Ohshima M, et al. YAP and TAZ modulate cell phenotype in a subset of small cell lung cancer. *Cancer Sci* 2016;107:1755-66.
70. Murai F, Koinuma D, Shinozaki-Ushiku A, et al. EZH2 promotes progression of small cell lung cancer by suppressing the TGF-beta-Smad-ASCL1 pathway. *Cell Discov* 2015;1:15026.
71. Ramsay RG, Gonda TJ. MYB function in normal and cancer cells. *Nat Rev Cancer* 2008;8:523-34.
72. Ferrarotto R, Heymach JV, Glisson BS. MYB-fusions and other potential actionable targets in adenoid cystic carcinoma. *Curr Opin Oncol* 2016;28:195-200.
73. Griffin CA, Baylin SB. Expression of the c-myc oncogene in human small cell lung carcinoma. *Cancer Res* 1985;45:272-5.
74. Denny SK, Yang D, Chuang CH, et al. Nfib promotes metastasis through a widespread increase in chromatin accessibility. *Cell* 2016;166:328-42.
75. Allison Stewart C, Tong P, Cardnell RJ, et al. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer. *Oncotarget* 2017;8:28575-87.
76. Gardner EE, Lok BH, Schneeberger VE, et al. Chemosensitive Relapse in Small Cell Lung Cancer Proceeds through an EZH2-SLFN11 Axis. *Cancer Cell* 2017;31:286-99.
77. Hubaux R, Thu KL, Coe BP, et al. EZH2 promotes E2F-driven SCLC tumorigenesis through modulation of apoptosis and cell-cycle regulation. *J Thorac Oncol* 2013;8:1102-6.
78. Campbell LL, Polyak K. Breast tumor heterogeneity: cancer stem cells or clonal evolution? *Cell Cycle* 2007;6:2332-8.

Cite this article as: Zhang W, Girard L, Zhang YA, Haruki T, Papari-Zareei M, Stastny V, Ghayee HK, Pacak K, Oliver TG, Minna JD, Gazdar AF. Small cell lung cancer tumors and preclinical models display heterogeneity of neuroendocrine phenotypes. *Transl Lung Cancer Res* 2018;7(1):32-49. doi: 10.21037/tlcr.2018.02.02

Supplementary

Table S1 The list of top 25 genes associated with NE differentiation

Illumina human WG6 V3 probe ID	Symbol	Log ratio	Neg log <i>t</i> test P value	Volcano plot rank metric	NE class mean expression	Non-NE class mean expression
ILMN_2234697	<i>BEX1</i>	9.49	47.9	101.92	13.67	4.18
ILMN_1701653	<i>ASCL1</i>	8.76	24.0	80.46	12.37	3.61
ILMN_1797668	<i>INSM1</i>	8.06	44.7	78.94	12.72	4.66
ILMN_1669410	<i>CHGA</i>	7.44	49.6	74.30	11.40	3.96
ILMN_1698179	<i>TAGLN3</i>	8.06	35.1	73.81	11.89	3.83
ILMN_2212999	<i>KIF5C</i>	7.08	50.6	71.26	11.49	4.41
ILMN_1789541	<i>CRMP1</i>	7.43	41.2	68.91	12.31	4.87
ILMN_2197946	<i>SCG3</i>	7.39	41.7	68.66	11.25	3.86
ILMN_1768705	<i>SYT4</i>	7.81	29.7	67.89	11.16	3.35
ILMN_1756928	<i>RTN1</i>	7.41	36.9	66.12	11.30	3.90
ILMN_1721167	<i>MYT1</i>	6.33	50.7	64.65	10.02	3.69
ILMN_1701483	<i>SYP</i>	5.21	56.6	62.80	8.94	3.73
ILMN_1759330	<i>KIF1A</i>	7.52	26.0	62.18	13.00	5.49
ILMN_1681737	<i>TMSB15A</i>	7.10	33.5	60.57	12.18	5.07
ILMN_2407703	<i>SYN1</i>	5.21	52.4	59.04	8.99	3.78
ILMN_1717934	<i>SYT11</i>	6.70	37.8	58.67	12.30	5.60
ILMN_1756715	<i>RUNDC3A</i>	5.60	46.5	56.10	9.46	3.86
ILMN_1811387	<i>TFF3</i>	7.19	21.0	55.86	11.99	4.79
ILMN_1765966	<i>CHGB</i>	6.25	39.4	55.51	11.14	4.88
ILMN_1655498	<i>FAM57B</i>	6.21	38.7	54.59	11.64	5.43
ILMN_1661491	<i>SH3GL2</i>	6.42	35.2	54.19	10.62	4.20
ILMN_1760246	<i>BSN</i>	4.38	49.4	53.02	8.66	4.28
ILMN_1658809	<i>SEZ6</i>	6.27	33.5	51.67	9.86	3.58
ILMN_1731640	<i>TMSB15B</i>	6.25	33.2	51.33	11.59	5.33
ILMN_1681234	<i>CELF3</i>	5.83	37.7	50.74	9.04	3.21

NE, neuroendocrine.

Table S2 The list of top 25 genes not associated with NE differentiation

Illumina human WG6 V3 probe ID	Symbol	Log ratio	Neg log <i>t</i> test P value	Volcano plot rank metric	NE class mean expression	Non-NE class mean expression
ILMN_1837428	<i>RAB27B</i>	-5.48	32.7	44.40	4.09	9.57
ILMN_1726245	<i>TGFBR2</i>	-5.60	32.2	44.94	4.42	10.02
ILMN_1755649	<i>SLC16A5</i>	-5.60	32.6	45.28	3.96	9.56
ILMN_2046730	<i>S100A10</i>	-6.45	18.2	45.41	8.27	14.72
ILMN_2334210	<i>ITGB4</i>	-5.53	34.6	46.20	3.76	9.30
ILMN_1709479	<i>YAP1</i>	-5.71	34.8	47.70	3.95	9.66
ILMN_1803788	<i>LGALS3</i>	-4.82	41.8	47.77	4.12	8.94
ILMN_1699354	<i>EPHA2</i>	-4.64	42.9	47.98	3.79	8.43
ILMN_1728049	<i>S100A16</i>	-6.27	30.5	49.75	4.84	11.11
ILMN_1656057	<i>PLAU</i>	-6.39	29.3	50.20	4.88	11.26
ILMN_1677814	<i>ABCC3</i>	-6.56	29.2	52.01	4.80	11.36
ILMN_1678143	<i>ARHGDIB</i>	-6.72	25.9	52.10	4.25	10.97
ILMN_2188264	<i>CYR61</i>	-6.28	35.7	53.26	4.86	11.14
ILMN_1713829	<i>PTGES</i>	-6.28	35.8	53.29	3.91	10.19
ILMN_1688480	<i>CCND1</i>	-7.11	20.8	54.61	5.87	12.97
ILMN_1673352	<i>IFITM2</i>	-6.90	27.6	55.01	5.90	12.80
ILMN_1805750	<i>IFITM3</i>	-6.93	28.1	55.61	5.60	12.53
ILMN_1714567	<i>AHNAK</i>	-6.08	42.2	56.14	4.90	10.98
ILMN_1735220	<i>CAV2</i>	-6.08	43.3	56.92	4.19	10.27
ILMN_1739001	<i>TACSTD2</i>	-7.08	27.4	57.09	4.65	11.72
ILMN_1663866	<i>TGFBI</i>	-7.36	30.3	62.02	4.94	12.30
ILMN_1801616	<i>EMP1</i>	-7.01	38.6	62.53	3.62	10.63
ILMN_2149226	<i>CAV1</i>	-7.72	40.9	72.23	4.01	11.73
ILMN_2184184	<i>ANXA1</i>	-8.22	30.3	74.01	4.85	13.07
ILMN_1810289	<i>MYOF</i>	-7.84	56.2	83.26	4.13	11.97

NE, neuroendocrine.

Table S3 The functions of top 25 genes associated with NE differentiation

Symbol	Gene name	Category	Function
<i>BEX1</i>	Brain expressed X-linked 1	N	Signaling adapter molecule involved in cell cycle progression and neuronal differentiation.
<i>ASCL1</i>	Achaete-scute family bHLH transcription factor 1	N, NE	This gene encodes a member of the basic helix-loop-helix (BHLH) family of transcription factors. This protein plays a role in the neuronal commitment and differentiation and in the generation of olfactory and autonomic neurons
<i>INSM1</i>	Insulinoma associated 1	NE	This gene is a sensitive marker for neuroendocrine differentiation of human lung tumors
<i>CHGA</i>	chromogranin A	N, NE	The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins
<i>TAGLN3</i>	Transgelin 3	N	Actin filament binding, mainly in neurons
<i>KIF5C</i>	Kinesin family member 5C	N	The protein encoded by this gene is a kinesin heavy chain subunit involved in the transport of cargo within the central nervous system
<i>CRMP1</i>	Collapsin response mediator protein 1	N	This gene encodes a member of a family of cytosolic phosphoproteins expressed exclusively in the nervous system
<i>SCG3</i>	Secretogranin III	NE	The protein encoded by this gene is a member of the chromogranin/secretogranin family of neuroendocrine secretory proteins
<i>SYT4</i>	Synaptotagmin 4	N, NE	Induced by depolarization in PC12 pheochromocytoma cells and in the hippocampus, and may function as a negative regulator of neurotransmitter release
<i>RTN1</i>	Reticulon 1	N, NE	Belongs to the family of reticulon encoding genes. Reticulons are associated with the endoplasmic reticulum, and are involved in NE secretion or in membrane trafficking in neural and NE cells
<i>MYT1</i>	Myelin transcription factor 1	N	The protein encoded by this gene is a member of a family of neural specific, zinc finger-containing DNA-binding proteins. The protein binds to the promoter regions of proteolipid proteins of the central nervous system and plays a role in the developing nervous system
<i>SYP</i>	Synaptophysin	N, NE	This gene encodes an integral membrane protein of small synaptic vesicles in brain and endocrine cells
<i>KIF1A</i>	Kinesin family member 1A	N	The protein encoded by this gene is a member of the kinesin family and functions as an anterograde motor protein that transports membranous organelles along axonal microtubules
<i>TMSB15A</i>	Thymosin beta 15a	O	Role in the organization of the cytoskeleton. Binds to and sequesters actin monomers (G actin) and therefore inhibits actin polymerization
<i>SYN1</i>	Synapsin I	N	This gene is a member of the synapsin gene family. Synapsins encode neuronal phosphoproteins which associate with the cytoplasmic surface of synaptic vesicles.
<i>SYT11</i>	Synaptotagmin 11	N	This gene is a member of the synaptotagmin gene family and encodes a protein that mediates calcium-dependent regulation of membrane trafficking in synaptic transmission.
<i>RUNDC3A</i>	RUN domain containing 3A	O	GO annotations related to this gene include GTPase regulator activity and guanylate cyclase activator activity
<i>TFF3</i>	Trefoil factor 3	O	A member of the trefoil family which is stable secretory proteins expressed in gastrointestinal mucosa. Function not fully defined
<i>CHGB</i>	Chromogranin B	N, NE	This gene encodes a tyrosine-sulfated secretory protein abundant in peptidergic endocrine cells and neurons
<i>FAM57B</i>	Family with sequence similarity 57 member B	O	This gene encodes a transmembrane protein, which may be a likely target of peroxisome proliferator-activated receptor gamma (PPAR-gamma)
<i>SH3GL2</i>	SH3 domain containing GRB2 like 2, endophilin A1	N	Implicated in synaptic vesicle endocytosis. May recruit other proteins to membranes with high curvature. Required for BDNF-dependent dendrite outgrowth
<i>BSN</i>	Bassoon presynaptic cytomatrix protein	N	The protein encoded by this gene is thought to be a scaffolding protein involved in organizing the neuronal presynaptic cytoskeleton
<i>SEZ6</i>	Seizure related 6 homolog	N	May play a role in cell-cell recognition and in neuronal membrane signaling
<i>TMSB15B</i>	Thymosin beta 15B	O	Similar role as TMSB15A
<i>CELF3</i>	CUGBP Elav-like family member 3	O	Members of this protein family regulate pre-mRNA alternative splicing and may also be involved in mRNA editing

Table S4 The functions of top 25 genes not associated with NE differentiation

Symbol	Gene name	Category	Function
<i>RAB27B</i>	RAB27B, member RAS oncogene family	O	Members of the Rab protein family, including RAB27B, are prenylated, membrane-bound proteins involved in vesicular fusion and trafficking
<i>TGFBR2</i>	Transforming growth factor beta receptor 2	O	The protein encoded by this gene is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with TGF-beta receptor type-1, and binds TGF-beta
<i>SLC16A5</i>	Solute carrier family 16 member 5	O	This gene encodes a member of the monocarboxylate transporter family and the major facilitator superfamily. The encoded protein is localized to the cell membrane and acts as a proton-linked transporter of bumetanide
<i>S100A10</i>	S100 calcium binding protein A10	O	The protein encoded by this gene is a member of the S100 family of proteins containing 2 EF-hand calcium-binding motifs. S100 proteins are involved in the regulation of a number of cellular processes such as cell cycle progression and differentiation
<i>ITGB4</i>	Integrin subunit beta 4	O	This gene encodes the integrin beta 4 subunit, a receptor for the laminins and is likely to play a pivotal role in the biology of invasive carcinoma
<i>YAP1</i>	Yes associated protein 1	O	This gene encodes a downstream nuclear effector of the Hippo signaling pathway which is involved in development, growth, repair, and homeostasis
<i>LGALS3</i>	Galectin 3	O	This gene encodes a member of the galectin family of carbohydrate binding proteins. Members of this protein family have an affinity for beta-galactosides. The protein exhibits antimicrobial activity against bacteria and fungi
<i>EPHA2</i>	EPH receptor A2	O	This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system
<i>S100A16</i>	S100 calcium binding protein A16	O	GO annotations related to this gene include poly(A) RNA binding and protein homodimerization activity
<i>PLAU</i>	Plasminogen activator, urokinase	O	This gene encodes a secreted serine protease that converts plasminogen to plasmin
<i>ABCC3</i>	ATP binding cassette subfamily C member 3	O	The protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters. This protein is a member of the MRP subfamily which is involved in multi-drug resistance
<i>ARHGD1B</i>	Rho GDP dissociation inhibitor beta	O	Members of the Rho (or ARH) protein family and other Ras-related small GTP-binding proteins are involved in diverse cellular events, including cell signaling, proliferation, cytoskeletal organization, and secretion
<i>CYR61</i>	Cysteine rich angiogenic inducer 61	O	The secreted protein encoded by this gene is growth factor-inducible and promotes the adhesion of endothelial cells. The encoded protein interacts with several integrins and with heparan sulfate proteoglycan. This protein also plays a role in cell proliferation, differentiation, angiogenesis, apoptosis, and extracellular matrix formation
<i>PTGES</i>	Prostaglandin E synthase	O	The protein encoded by this gene is a glutathione-dependent prostaglandin E synthase. The expression of this gene has been shown to be induced by proinflammatory cytokine interleukin 1 beta (IL1B). Its expression can also be induced by tumor suppressor protein TP53, and may be involved in TP53 induced apoptosis
<i>CCND1</i>	Cyclin D1	O	The protein encoded by this gene belongs to the highly conserved cyclin family, whose members are characterized by a dramatic periodicity in protein abundance throughout the cell cycle
<i>IFITM2</i>	Interferon induced transmembrane protein 2	O	The protein encoded by this gene is an interferon-induced membrane protein that helps confer immunity to influenza A H1N1 virus, West Nile virus, and dengue virus
<i>IFITM3</i>	Interferon induced transmembrane protein 3	O	The protein encoded by this gene is an interferon-induced membrane protein that helps confer immunity to influenza A H1N1 virus, West Nile virus, and dengue virus
<i>AHNAK</i>	AHNAK nucleoprotein	O	The encoded protein may play a role in such diverse processes as blood-brain barrier formation, cell structure and migration, cardiac calcium channel regulation, and tumor metastasis
<i>CAV2</i>	Caveolin 2	O	The protein encoded by this gene is a major component of the inner surface of caveolae, small invaginations of the plasma membrane, and is involved in essential cellular functions, including signal transduction, lipid metabolism, cellular growth control and apoptosis
<i>TACSTD2</i>	Tumor-associated calcium signal transducer 2	O	This intronless gene encodes a carcinoma-associated antigen. This antigen is a cell surface receptor that transduces calcium signals
<i>TGFBI</i>	Transforming growth factor beta induced	O	This gene encodes an RGD-containing protein that binds to type I, II and IV collagens. The protein is induced by transforming growth factor-beta and acts to inhibit cell adhesion
<i>EMP1</i>	Epithelial membrane protein 1	O	Epithelial membrane associated protein reportedly involved in several cellular functions
<i>CAV1</i>	Caveolin 1	O	The scaffolding protein encoded by this gene is the main component of the caveolae plasma membranes found in most cell types
<i>ANXA1</i>	Annexin A1	O	This gene encodes a membrane-localized protein that binds phospholipids. This protein inhibits phospholipase A2 and has anti-inflammatory activity
<i>MYOF</i>	Myoferlin	O	The protein encoded by this gene is a type II membrane protein that is structurally similar to dysferlin. It is a member of the ferlin family and associates with both plasma and nuclear membranes. The protein contains C2 domains that play a role in calcium-mediated membrane fusion events, suggesting that it may be involved in membrane regeneration and repair

*, in the category column, the pre-existing functional concept of the gene is stated—neural (N), neuroendocrine (NE), both (N + NE) or other (O). **, most, but not all of this information comes from GeneCards (<http://www.genecards.org/>).